Anticancer agent 315
Anticancer agent 315 is an antitumor agent. Anticancer agent 315 binds to the active pocket of thymidylate synthase via forming strong hydrogen bonds with Lys487 and Ala498, stabilizing the arrangement of the ligand within the pocket. Anticancer agent 315 inhibits the proliferation of tumor cells. Anticancer agent 315 can be used for the research of liver cancer and breast cancer.
For research use only. We do not sell to patients.
- Formula: C23H17N11O3S
- Molecular Weight:527.52
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Anticancer agent 315 (compound 23) potently inhibits the viability of HepG2 and MCF-7 cancer cells, while exhibiting low toxicity toward WI-38 and VERO normal cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HepG2 and MCF-7 cancer cells, WI-38 and VERO normal cells
-
Concentration:/
-
Incubation Time:/
-
Result:Had IC50 values of 15.9 µM and 18.0 µM for HepG2 and MCF-7 cancer cells.
Had IC50 values of 40.2 µM and 45.7 µM for WI-38 and VERO normal cells.
Chemical Information
-
Molecular Weight 527.52
-
Formula C23H17N11O3S
-
SMILES
O=C(C1=C(N/N=C(C#N)/C#N)NN=C1NC2=CC=CC=C2)NC3=CC=C(S(=O)(NC4=NC=CC=N4)=O)C=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)